Perimenopause is the multi-year hormonal transition that precedes menopause. It is the gradual decline in ovarian function during which estrogen, progesterone, follicle-stimulating hormone (FSH), and luteinizing hormone (LH) shift erratically before your periods stop for good. It is distinct from menopause itself, which is a single point in time defined as 12 consecutive months without a menstrual period. Perimenopause typically begins in your early to mid-40s, though for some women it starts in the late 30s. It can last anywhere from a few months to a decade. During this window your cycles often stay regular while symptoms begin to surface: sleep disruption, mood changes, cognitive fog, weight redistribution. They are frequently put down to stress, aging, or thyroid dysfunction.
Perimenopause at a glance
- Onset: most commonly between ages 40 and 44, and in the late 30s for some women.
- Length: the transition to your final period averages around four years, with a published range of about 0.3 to 10 years.
- End point: the average age at the final menstrual period in the United States is approximately 51.
- Diagnosis: perimenopause is identified from your cycle pattern and symptoms, not from one hormone test. The European Society of Endocrinology 2025 guideline states that biochemical testing is not necessary over age 45.
- Hormones: progesterone usually declines before estradiol does. That is why sleep and anxiety symptoms often start while your cycles are still regular.
- Uncertainty is normal: in a Menopause Society survey reported in July 2026, 34% of US women aged 35 and over were unsure of their stage.
Not being sure whether this is perimenopause is the norm rather than the exception. The Menopause Society surveyed more than 7,600 US women aged 35 and over and reported the results in July 2026. Of those women, 34% could not say which reproductive stage they were in. Uncertainty was highest between the ages of 40 and 44, where 42% were unsure. It also ran high among women carrying a severe symptom burden, at 37%. The survey put 56% of that confusion down to symptoms that were hard to interpret and 28% down to gaps in knowledge.
In this article
- How perimenopause differs from menopause, and why the distinction matters clinically
- The STRAW+10 staging framework and where most women find themselves
- A 34-symptom inventory the field now recognizes
- How long the perimenopausal window typically lasts, and why ethnicity influences that
- Why standard primary-care labs frequently look normal during perimenopause
- The functional testing categories a deeper workup may include
- What functional medicine practitioners look for, plus one patient's experience
- Where Texas state policy on menopause coverage currently stands
What perimenopause actually is: a transition, not a switch
Perimenopause is best understood as a moving biological state rather than a discrete event. Your ovarian follicle reserve declines steadily from your mid-30s. As fewer follicles respond to FSH each cycle, anovulatory cycles become more common and progesterone production becomes inconsistent. Estradiol (E2) begins to fluctuate widely, sometimes spiking higher than in your earlier reproductive years before dropping sharply. The Menopause Society defines menopause itself as the date of your final menstrual period, confirmed retrospectively after 12 months of amenorrhea. Everything before that confirmed date (symptoms, cycle changes, hormonal volatility) falls within perimenopause.
This distinction matters clinically. Many women in their 40s are told they are "too young" for menopause and that nothing is wrong because periods are still happening. The published staging literature contradicts this framing. The Stages of Reproductive Aging Workshop + 10 (STRAW+10), published in 2012 in The Journal of Clinical Endocrinology & Metabolism, formally identifies multiple stages before the final menstrual period. In those stages you are unambiguously in transition, whether or not your cycles still arrive monthly. Recognizing perimenopause as a stageable physiological process, rather than waiting for periods to stop, is what allows earlier and more accurate clinical conversations.
Three pieces of physiology drive the perimenopause transition.
Ovarian reserve declines from the mid-30s
Antral follicle count and anti-Müllerian hormone (AMH), the markers of remaining ovarian reserve, decline progressively from the mid-30s onward. That decline accelerates after age 37 or 38.
FSH rises, but not in a straight line
As fewer ovarian follicles respond, the hypothalamic-pituitary axis compensates by secreting more FSH. FSH itself fluctuates considerably from cycle to cycle, and from week to week within a cycle.
Progesterone falls years before estradiol
In perimenopause, progesterone often declines years before estradiol does. Ovulation becomes intermittent, so cycles that look normal on a calendar can be anovulatory. Those cycles produce no corpus luteum and therefore no meaningful luteal-phase progesterone. That is why sleep, anxiety, and luteal-phase symptoms frequently appear while you still cycle every 28 days.
Estradiol swings rather than declines
Estradiol behavior during perimenopause is counterintuitive. Rather than declining smoothly, estradiol often swings widely, including supraphysiologic peaks during the late-reproductive and early-transition stages. Harlow and colleagues documented this volatility in their STRAW+10 review.
Harlow and colleagues noted that symptom intensity often tracks the size of the fluctuation rather than the absolute level. This is one reason you can have seemingly "adequate" estradiol on a single blood draw and still experience hot flashes, breast tenderness, and migraines. It is the rate and amplitude of change, not the static value, that drives much of the symptom picture.
The STRAW+10 framework: where you are matters
The STRAW+10 system is the international reference standard for describing reproductive aging and is used in research, clinical guidelines, and increasingly in functional medicine practice. It divides the reproductive lifespan into seven stages anchored to the final menstrual period (FMP).
| Stage | Name | Cycle pattern | Key endocrine features |
|---|---|---|---|
| −5 | Early reproductive | Variable to regular | Normal FSH, preserved AMH and antral follicle count |
| −4 | Peak reproductive | Regular | Normal FSH; AMH begins gradual decline |
| −3 | Late reproductive | Subtle cycle changes; flow or length variability | Low AMH, low antral follicle count, occasional early-cycle FSH rises |
| −2 | Early menopausal transition | Persistent cycle-length variation of ≥7 days | Elevated, variable early-follicular FSH; low AMH |
| −1 | Late menopausal transition | Interval of amenorrhea ≥60 days | FSH frequently >25 IU/L; estradiol highly variable |
| +1a/b/c | Early post-menopause | 12 months amenorrhea, then up to 5–8 years | FSH stabilizing high; estradiol stabilizing low |
| +2 | Late post-menopause | Established post-menopause | Endocrine stability; somatic aging dominates |
The two stages most women are in
The two stages most relevant if you are searching "what is perimenopause" are Stage −3 (late reproductive) and Stage −2 (early menopausal transition). In Stage −3, your cycles are typically still regular, but subtle changes in flow, mood, or sleep are already present and reflect declining ovarian reserve. Stage −2 is defined by persistent variation in cycle length of seven days or more. Harlow and colleagues noted that this is the point at which most women begin experiencing recognizable vasomotor symptoms, though not all do, and the timing varies. Mapping where you sit on STRAW+10 is the foundation of any informed perimenopause workup.
What the +10 update changed
The STRAW+10 update added important refinements over the original 2001 framework. Stage −3 was subdivided into Stage −3b (regular cycles, low AMH) and Stage −3a (subtle cycle changes, low AMH, occasionally elevated early-follicular FSH). Stage +1 was subdivided into +1a (the first 12 months after the final menstrual period), +1b (the following one to two years of continued endocrine change), and +1c (the remaining three to six years of stabilization). These subdivisions matter because symptom trajectories and cardiovascular, bone, and cognitive risk profiles differ across them. The early post-menopausal years (+1a and +1b) are a particularly active window of physiological change, not a static endpoint.
When staging does not apply
Two other points are worth emphasizing. First, the STRAW+10 framework explicitly acknowledges that staging may be modified, or unreliable, if you have had a hysterectomy or endometrial ablation, use certain hormonal contraception, have polycystic ovary syndrome, or have a chronic illness that disrupts the hypothalamic-pituitary-ovarian axis. In those cases the criteria shift toward endocrine and ovarian-reserve markers (AMH, antral follicle count) rather than menstrual-cycle pattern. Second, calendar age alone is a poor proxy for reproductive stage. Two women aged 45 can be in completely different stages, one still in Stage −4 and the other already in Stage −1, depending on ovarian reserve, smoking history, surgical history, and genetics.
Symptoms beyond hot flashes: the 34 commonly reported
Hot flashes and night sweats, collectively called vasomotor symptoms (VMS), are the most-cited manifestations of perimenopause. But they account for only a fraction of what women report. The clinical literature, summarized by The Menopause Society, now recognizes a much broader symptom profile. The widely circulated "34 symptoms" inventory consolidates these into a single checklist. It helps you and your clinician connect seemingly unrelated complaints to a common hormonal driver.
What you expect and what you actually get are often different things. A companion global study run with the Flo app covered more than 17,000 women in 158 countries, and the Menopause Society reported it on 27 January 2026. Hot flashes were the symptom women most expected to have, named by 71%, followed by sleep problems at 68% and weight change at 65%. The picture among women aged 35 and over who were already in the transition looked different. There the most reported symptoms were fatigue and exhaustion, both at 83%, then irritability at 80%, depressive mood at 77% and sleep problems at 76%. The symptoms you anticipate are not the ones that tend to dominate day to day.
- Hot flashes, reported by approximately 80% of women across the menopausal transition
- Night sweats, present in roughly 50–70% of perimenopausal women
- Irregular periods, near-universal in mid-to-late perimenopause
- Heavier or lighter bleeding
- Shortened or lengthened cycle intervals
- Sleep-onset insomnia
- Early-morning awakening
- Anxiety, including new-onset panic episodes
- Low mood or depressive symptoms
- Irritability and rage spikes
- Brain fog and word-finding difficulty
- Short-term memory lapses
- Reduced concentration
- Fatigue not relieved by sleep
- Headaches, including new or worsening migraines
- Dizziness or vertigo episodes
- Joint pain and stiffness
- Muscle aches
- Breast tenderness, often cyclical
- Bloating and digestive changes
- Weight gain, especially abdominal
- Hair thinning on the scalp
- Facial hair growth
- Dry, itchy, or thinning skin
- Formication (skin-crawling sensation)
- Vaginal dryness
- Dyspareunia (painful intercourse)
- Reduced libido
- Urinary urgency or recurrent UTIs
- Heart palpitations
- Tinnitus or altered hearing
- Burning mouth or altered taste
- Brittle nails
- Body odor changes
Prevalence varies. Vasomotor symptoms are the most-studied. The SWAN cohort reported a median total VMS duration of 7.4 years in symptomatic women, with significant ethnic variation. Cognitive symptoms have a measurable biological substrate. Estradiol modulates brain-derived neurotrophic factor (BDNF) expression in the hippocampus and prefrontal cortex. And research on the estrogen–BDNF pathway describes one mechanism behind the verbal-memory and processing-speed changes women commonly notice.
Several symptom clusters deserve specific mention because they are commonly misattributed to other diagnoses.
New-onset anxiety and panic
New-onset anxiety and panic in your early-to-mid 40s, particularly with no prior psychiatric history, is frequently a perimenopausal presentation rather than an isolated psychiatric event. The mechanism involves declining progesterone, which is metabolized to allopregnanolone, a positive allosteric modulator of the GABA-A receptor. When progesterone falls or becomes erratic, GABAergic tone drops. Anxiety, irritability, and sleep-onset insomnia frequently follow.
The risk of depressive symptoms is measurably higher in perimenopause. Badawy and colleagues pooled 17 cohorts covering 16,061 women in the Journal of Affective Disorders in 2024. The odds of depressive symptoms were higher in perimenopause than in the years before it (odds ratio 1.40, confidence interval 1.21 to 1.61). The same analysis found no comparable increase after menopause. That pattern points to the hormonal fluctuation itself rather than to low levels.
Joint pain and morning stiffness
Joint pain, often morning stiffness in the hands, knees, or hips, is increasingly recognized as a perimenopausal symptom. Estrogen has direct effects on synovial tissue, cartilage, and pain perception, and arthralgia is now well documented in The Menopause Society's symptom literature.
Palpitations
Heart palpitations (typically transient, non-sustained, and benign) are reported by approximately 25% to 40% of perimenopausal women and reflect autonomic shifts tied to estradiol fluctuation. New palpitations always warrant cardiac evaluation to rule out arrhythmia.
Genitourinary syndrome of menopause
The genitourinary syndrome of menopause (GSM) covers vaginal dryness, dyspareunia, urinary urgency, and recurrent UTIs. GSM typically emerges in late perimenopause and progresses through the post-menopausal years. Unlike vasomotor symptoms, which often improve over time, GSM is generally progressive without intervention, because the underlying tissue changes are driven by sustained low estradiol rather than fluctuation. The Menopause Society guidance treats GSM as a distinct clinical entity warranting separate discussion.
Migraine pattern changes
Migraine patterns frequently change during perimenopause. If you have had menstrual migraine, you may experience more frequent or severe attacks during the transition before they stabilize in post-menopause. A smaller group develops new-onset migraine in their 40s for the first time.
How long does perimenopause last? (SWAN cohort data)
Perimenopause lasts about four years on average. The overall menopausal transition, from the first persistent cycle irregularity to the final menstrual period, has a published range of approximately 0.3 to 10 years. When total symptom duration is measured, including post-menopausal years in which symptoms persist, the numbers are considerably longer. In the SWAN vasomotor-symptom analysis, median total VMS duration was 7.4 years across the cohort.
The Study of Women's Health Across the Nation (SWAN) is the largest and longest-running multi-ethnic longitudinal study of the menopausal transition. SWAN findings have reshaped what "normal" perimenopause looks like. Ethnic stratification in the SWAN vasomotor data is striking:
- African American women: median 10.1 years of vasomotor symptoms
- Hispanic women: median 8.9 years
- Non-Hispanic White women: median 6.5 years
- Chinese women: median 5.4 years
- Japanese women: median 4.8 years
How long hot flashes and night sweats last: SWAN medians
Median total duration of vasomotor symptoms in the Study of Women's Health Across the Nation (SWAN), as reported in this article. Medians are population figures; individual duration varies widely.
SWAN also found that women whose hot flashes began while cycles were still regular, or in early perimenopause, experienced symptoms for a median of 11.8 years. That is far longer than women whose vasomotor symptoms began only after periods stopped. Subsequent SWAN analyses have described disparities in reproductive aging and midlife health between Black and White women. Those include earlier onset of the transition and higher cumulative symptom burden among Black participants. These data have direct clinical implications. Any framework that assumes a "standard" 4-year perimenopause underestimates the experience of a substantial subset of women.
Other factors associated with earlier onset and/or longer total duration in the SWAN literature and related cohorts include current smoking, lower educational attainment, nulliparity, and a family history of early menopause. Higher baseline body mass index is another, and it influences both onset and symptom severity through aromatase-mediated peripheral estrogen production. Conversely, hormonal contraceptive use, parity, and certain dietary patterns have been associated with a later final menstrual period in observational studies, though causal inference from these associations is limited. The clinical takeaway is that perimenopause duration is highly individual. If you are in your mid-40s with several years of escalating symptoms, you are not an outlier. You are well within the published distribution.
SWAN has also begun linking what happens during the transition to what comes later. A SWAN analysis of 1,140 women, published in Alzheimer's and Dementia on 23 December 2025, scored cardiovascular health across the transition using Life's Essential 8. Women with low cardiovascular health showed 11% greater declines in subjective cognitive function in later years. Women whose cardiovascular health worsened showed 7% greater declines, and those with moderate health 5%. Improving health behaviors between the premenopausal and early perimenopausal years was protective. This is observational work, so it cannot prove cause. It does suggest the transition years are a window worth using.
Hormone behavior across the perimenopause window
The table below summarizes typical population-level patterns for the key reproductive hormones across the STRAW+10 stages most relevant to perimenopause. Individual values vary considerably; these are reference patterns, not diagnostic cutoffs.
| Hormone | Late reproductive (35–42) | Early peri (42–46) | Late peri (47–51) | Post-menopause (52+) | What it means clinically |
|---|---|---|---|---|---|
| FSH (early follicular) | 4–10 IU/L | Variable; intermittent rises into 15–20 IU/L | Frequently >25 IU/L, still fluctuating | Sustained >30–40 IU/L | Rising FSH reflects declining follicular response; a single value is not diagnostic |
| Estradiol (E2) | ~50–400 pg/mL across cycle | Wide swings; supraphysiologic peaks alternating with low troughs | Predominantly low; occasional surges | Typically <30 pg/mL | Symptom severity often tracks the magnitude of swings rather than the absolute level |
| Progesterone (luteal) | 10–20 ng/mL in ovulatory cycles | Frequently low due to anovulatory cycles | Often undetectable; rare ovulation | Negligible | Progesterone usually declines before estradiol, contributing to sleep and anxiety symptoms |
| LH | Normal cyclical pattern | Variable; intermittent elevation | Persistently elevated | Sustained elevation | Rises in parallel with FSH as ovarian feedback diminishes |
| AMH | Gradual decline from ~2–4 ng/mL | Typically <1 ng/mL | Often undetectable | Undetectable | AMH reflects remaining ovarian reserve and trends downward years before FSH rises |
Reference ranges drawn from Endocrine Society clinical practice guidelines and SWAN cohort publications. Cycle-day timing of a blood draw substantially affects FSH, estradiol, and LH values.
The four hormones across the transition
LR late reproductive (35–42) · EP early perimenopause (42–46) · LP late perimenopause (47–51) · PM post-menopause (52+)
Every panel is one row of the reference table above, on its own scale. A solid block is a published numeric range. An arrow means the source gives a floor rather than a ceiling (“frequently above 25”). A block on the baseline means undetectable or negligible. A hatched column is where the table describes the pattern in words rather than giving a value. Those hatched columns fall in the middle stages, which is the reason a single blood draw is so hard to read during perimenopause.
Why standard labs often look "normal" in perimenopause
One of the most common experiences in perimenopause is being told your bloodwork is "normal" while your symptoms continue to escalate. There are several structural reasons for this, and none of them mean you are imagining your symptoms.
One blood draw is one point on a moving curve
A single blood draw is one moment on a fluctuating curve. Perimenopausal hormone production is highly variable, and estradiol can range from undetectable to supraphysiologic levels within a single month. The Endocrine Society's clinical practice guidelines note that FSH and estradiol values during the transition are diagnostically limited for precisely this reason. That is why STRAW+10 staging relies primarily on menstrual-cycle criteria rather than a single hormone level.
Reference ranges ignore cycle day and stage
Reference ranges on most standard panels are built from broad adult populations. They do not account for cycle day, reproductive stage, or symptom context. A TSH of 3.8 mIU/L is flagged as normal on most lab reports. Yet it sits in the upper quartile of the reference range, and it may not reflect optimal thyroid status if you are symptomatic.
The markers that explain symptoms are not on the panel
Standard primary care panels typically do not test the markers that explain perimenopausal symptoms most directly. Those include progesterone (which often drops well before estradiol), DHEA-S, cortisol rhythm, free and total testosterone, sex hormone–binding globulin (SHBG), reverse T3, thyroid antibodies, and comprehensive iron studies. When those markers are absent from your workup, a "normal" result simply reflects the limited scope of testing, not the limits of your physiology.
Overlapping conditions get missed in 15 minutes
Several conditions that overlap with perimenopausal symptoms are frequently missed in a routine 15-minute primary-care visit. Training is part of the reason. In 2023 the journal Menopause published a survey of 99 US OB/GYN residency program directors. As Healio reported, only 31.3% of programs had a dedicated menopause curriculum. Another 92.9% wanted a national standard. Directors rated their satisfaction with the menopause education they provide at 3.75 out of 10.
Subclinical or early Hashimoto's thyroiditis can produce fatigue, weight gain, cognitive slowing, and hair changes that mirror perimenopause exactly. Without TPO and Tg antibodies on the panel, the autoimmune process can persist for years before TSH rises into the overtly hypothyroid range.
Iron deficiency without anemia, common if you have heavy perimenopausal bleeding, produces fatigue, cognitive symptoms, and exercise intolerance well before hemoglobin drops. Vitamin D insufficiency, B12 deficiency, and insulin resistance each add a symptom overlay that compounds the perimenopausal picture. The point is not that every symptomatic woman has all of these problems. It is that the perimenopausal years are a period of physiological vulnerability in which several overlapping issues commonly converge, and a narrow lab panel rarely captures the full picture.
Current guidelines say the same thing about testing. The European Society of Endocrinology published a guideline on 13 October 2025. It states that biochemical testing is not necessary for diagnosing or managing perimenopause in women older than 45. It was endorsed by the Endocrine Society, the European Menopause and Andropause Society and the British Menopause Society. The UK guideline NICE NG23, updated on 7 November 2024, takes the same position. Over 45 with typical symptoms, perimenopause is identified clinically, and an FSH test is reserved for ages 40 to 45 or under 40. If FSH is measured, the European guideline advises drawing it on day 2 to 5 of your cycle, or after more than 40 days without a period. A low AMH alongside a low estradiol and a high FSH supports the picture. A normal result on a test that was never designed to be diagnostic is not evidence that nothing is happening. What to test, and whether to test at all, is a decision to make with your own clinician.
Functional testing options for a fuller picture
Several categories of testing can extend the clinical picture beyond a basic metabolic and thyroid panel. The list below is descriptive: it explains what each category measures. It is not a recommendation to order any specific test. That is a clinical decision you make with your provider.
- Comprehensive thyroid panel. A full panel typically includes TSH, free T4, free T3, reverse T3, thyroid peroxidase antibodies (TPOAb), and thyroglobulin antibodies (TgAb). Reverse T3 reflects how your peripheral tissues are converting T4. Antibodies identify autoimmune thyroiditis (Hashimoto's) that may otherwise be missed.
- Dried-urine sex-hormone and cortisol testing (e.g., DUTCH). Dried-urine collection captures multiple data points across 24 hours. It quantifies hormone metabolites that serum testing does not show, particularly estrogen metabolites (2-OH, 4-OH, 16-OH pathways) and cortisol rhythm. The Institute for Functional Medicine summarizes the rationale for metabolite-pattern testing in its functional medicine educational resources.
- Ferritin and full iron studies. Heavy or erratic perimenopausal bleeding commonly depletes iron stores. Ferritin reflects storage iron and frequently shows depletion well before hemoglobin drops into the anemia range.
- Fasting insulin and HOMA-IR. Estrogen decline is associated with reduced insulin sensitivity. Fasting glucose alone often appears normal while fasting insulin is already rising, an early signal of metabolic shift.
- Inflammatory markers. High-sensitivity CRP and homocysteine can flag systemic inflammation that may underlie joint pain, mood changes, or cognitive symptoms.
- Comprehensive stool analysis. Gut microbial composition influences estrogen recirculation via the estrobolome, the gut bacteria producing β-glucuronidase. Dysbiosis is associated with altered estrogen metabolism, though the clinical literature is still developing.
What functional medicine practitioners look for
Functional medicine is an educational and clinical framework, popularized by organizations such as the Institute for Functional Medicine. It emphasizes root-cause analysis, systems biology, and the interaction between genetics, environment, and lifestyle. In the perimenopausal context, a functional workup typically considers several intersecting systems rather than treating your hormonal symptoms in isolation.
| Domain | What standard primary-care labs measure | What a functional workup may add |
|---|---|---|
| Thyroid | TSH (sometimes free T4) | Free T3, reverse T3, TPO and Tg antibodies |
| Sex hormones | FSH and estradiol (often only if menopause is suspected) | Progesterone, DHEA-S, total/free testosterone, SHBG, estrogen metabolites |
| Adrenal / stress | Rarely tested in primary care | Diurnal cortisol rhythm, DHEA-S |
| Metabolic | Fasting glucose, lipid panel, HbA1c | Fasting insulin, HOMA-IR, apoB, lipoprotein(a) |
| Nutrient status | Vitamin D (sometimes), B12 (occasionally) | Ferritin, full iron studies, RBC magnesium, homocysteine, MMA |
| Inflammation | Standard CRP (not high-sensitivity) | hs-CRP, homocysteine, fasting insulin as inflammatory proxy |
| Gut | Generally not tested unless GI symptoms | Comprehensive stool analysis, including markers of inflammation and microbial diversity |
Practitioners working within this framework also consider your sleep architecture, stress load, environmental exposures, and dietary patterns alongside laboratory data. The point is not that you need every test; most patients do not. It is that the diagnostic aperture is wider. Decisions about what to investigate are made in the context of your specific symptom pattern and your stage on the STRAW+10 framework. Treatment decisions, including any discussion of hormone therapy, lifestyle modification, or referral, are made individually with a prescribing clinician. The published evidence on hormone therapy itself is discussed in a separate article on hormone therapy considerations. That includes the 2017 re-analysis of the Women's Health Initiative trial (Manson et al., JAMA 2017) reporting mortality outcomes by age and time since menopause at initiation.
Heather's story: what comprehensive testing revealed
Heather presented after 3.5 years of escalating symptoms: debilitating headaches, brain fog, weight gain around the waist despite no change in diet, and persistent fatigue. Three previous providers had run TSH, a complete blood count, and a basic metabolic panel, told her her labs were "normal," and put her symptoms down to stress and aging. A comprehensive workup included a full thyroid panel with antibodies, dried-urine sex hormone testing, fasting insulin, ferritin, and a comprehensive stool analysis. It revealed Hashimoto's thyroiditis (elevated TPO antibodies with high-normal TSH), significant gut inflammation, and a substantial progesterone-to-estrogen imbalance consistent with her STRAW+10 stage. Within two weeks of beginning a personalized care plan, her headaches improved. Over three months, her brain fog lifted, her energy returned, and her waist measurement reduced by 12 inches.
Heather's story is shared with her consent. Her experience is one patient's, not a typical outcome. Results in perimenopause depend on a woman's individual physiology, the specific findings on her workup, the personalized plan developed with her clinician, and her adherence to that plan over time. This case is shared to illustrate the value of expanded testing in symptomatic women whose standard labs are "normal", not as evidence that any particular protocol will produce the same outcome for another reader.
Perimenopause care in Texas
Access to perimenopause care in Texas is shaped in part by state policy, and that policy is still forming. House Bill 3814, which would have required insurance coverage for menopause care, was referred to the Texas House Committee on Insurance on 26 March 2025. It saw no further action. Reporting by KPRC on 7 May 2025 placed Texas among 13 states then considering coverage mandates.
There has been movement since. On 20 August 2026 the Texas House created a Subcommittee on Maternal Health, Menopause and Access to Evidence-Based Medicine. Representative Katrina Pierson of House District 33 chairs it. Representatives Liz Campos and Joanne Shofner sit on it alongside her. The subcommittee was formed ahead of the 90th Legislature. None of this changes what your plan covers today, so it is worth confirming your own benefits before you arrange care.
When to consider booking a consult
The following situations are commonly cited in the menopause-medicine literature as warranting a more thorough evaluation than a basic primary-care visit. A consultation is worth considering if you are experiencing:
- Cycle changes lasting more than three months (shorter or longer intervals, heavier or lighter flow), particularly between ages 38 and 52
- New-onset insomnia, especially early-morning awakening, that has persisted for more than six weeks
- Anxiety, panic, or low mood that feels disproportionate to life circumstances or different in quality from previous episodes
- Cognitive symptoms (word-finding difficulty, lost trains of thought, slower processing) that are interfering with work performance
- Vasomotor symptoms (hot flashes or night sweats) of any frequency
- Weight gain, particularly abdominal, in the absence of dietary or activity changes
- Joint pain or stiffness without a clear orthopedic cause
- Symptoms in the presence of normal primary-care labs and a sense that something has been missed
- A family history of early menopause, autoimmune thyroid disease, or osteoporosis
This list is descriptive, not diagnostic. Many of the symptoms above have differential diagnoses outside of perimenopause, which is the reason a structured workup matters.
Waiting has a measurable cost. Mayo Clinic Proceedings published a study of 4,440 employed women aged 45 to 60 on 28 April 2023. Of those women, 13% had an adverse work outcome they attributed to menopause symptoms, and 11% had missed work. The authors put the annual cost of those lost workdays in the United States at $1.8 billion. That figure reached $26.6 billion once related medical spending was counted. Symptoms that are affecting your work are a reason to be evaluated, not a reason to push through.
FAQ
What is the difference between perimenopause and menopause?
Perimenopause is the transitional phase leading up to menopause, during which estrogen and progesterone fluctuate and symptoms begin. Menopause itself is a single retrospective diagnosis: the date 12 consecutive months after your final menstrual period. Everything before that point, including months or years of symptoms while your periods are still occurring, falls under perimenopause. The Menopause Society and the STRAW+10 framework both define the transition this way. Confusing the two leads many women to believe they are "too young for menopause," and delays evaluation when symptoms are already clinically significant.
At what age does perimenopause start?
Perimenopause most commonly begins between ages 40 and 44. SWAN cohort data show that for some women the late reproductive stage (Stage −3 in STRAW+10) begins as early as the late 30s. The average age at the final menstrual period in the United States is approximately 51. Onset is influenced by genetics, ethnicity, smoking status, autoimmune conditions, and prior surgical or chemotherapy exposure. If a first-degree relative had early menopause, you are statistically more likely to enter the transition earlier yourself.
Can I be in perimenopause if my periods are still regular?
Yes. The STRAW+10 framework explicitly identifies a late-reproductive stage (Stage −3) in which your cycles are typically still regular but subtle hormonal changes are already present: declining anti-Müllerian hormone (AMH), occasional early-cycle FSH rises, lower antral follicle counts. Many women in Stage −3 report sleep changes, mood shifts, or new headaches well before any visible change to their cycle. A regular period does not rule out perimenopausal physiology.
Why do my labs look normal when I feel awful?
Standard primary-care panels typically test TSH, a complete blood count, basic metabolic markers, and sometimes a single estradiol or FSH value. Perimenopausal hormone production fluctuates dramatically, sometimes within a single week, so one blood draw rarely captures the underlying instability. Standard panels also frequently omit progesterone, free T3, reverse T3, thyroid antibodies, fasting insulin, comprehensive iron studies, and metabolite testing. "Normal" on a narrow panel does not mean nothing is happening. It often means the relevant markers were not tested.
How long will my symptoms last?
Total duration varies widely. The SWAN cohort reported a median vasomotor-symptom duration of 7.4 years, with substantial ethnic variation. African American women experienced a median 10.1 years, Japanese women 4.8 years. Women whose hot flashes start while cycles are still regular tend to have the longest courses, with a median total duration of 11.8 years. Non-vasomotor symptoms (sleep, mood, cognition) follow less well-characterized trajectories, but they commonly improve in early post-menopause as hormone levels stabilize.
Is perimenopause treatable?
Multiple categories of intervention are discussed in the published menopause-medicine literature, from lifestyle and nutritional strategies to non-hormonal pharmacologic options to hormone therapy. The 2017 re-analysis of the Women's Health Initiative trial, published in JAMA, has reshaped the conversation around hormone therapy. It concerns the risks and benefits when therapy is started before age 60 or within 10 years of menopause onset. Which interventions are appropriate for you depends on your symptom profile, medical history, family history, and personal preferences. Those decisions should be made with a clinician who is familiar with menopause-medicine guidelines.
The labeling has since changed. On 10 November 2025 the FDA announced it was removing the boxed warnings from menopausal hormone therapy products. The first six revised labels were approved on 12 February 2026. The boxed warning about endometrial cancer stays on systemic estrogen-alone products. Prescribing had already fallen a long way. A JAMA Health Forum analysis of national survey data covering 13,048 postmenopausal women was published on 27 September 2024. It found hormone therapy use dropped from 26.9% in 1999 to 4.7% by 2020.
Nonhormonal options have moved too. The FDA approved elinzanetant, sold as Lynkuet, on 24 October 2025 for hot flashes and night sweats due to menopause. In the FDA trials snapshot it reduced hot flashes by about 9 to 10 per 24 hours at week 12, against 5 to 7 on placebo. It was studied only in women aged 40 to 65. Reported side effects included headache, fatigue, dizziness and sleepiness. The older drug in this class, fezolinetant (Veozah), gained a boxed warning for rare serious liver injury on 16 December 2024. Its label now calls for liver blood tests at baseline, monthly for the first three months, then at months 6 and 9. Whether either drug suits you, and how it would be monitored, is a decision for a prescribing clinician who knows your history.
About the author
Anna Evans MSN, APRN, FNP-C
Founder, Interlinked Wellness
Anna Evans, MSN, APRN, FNP-C is a board-certified Family Nurse Practitioner licensed in Texas. She founded Interlinked Wellness, a virtual functional medicine practice serving women across Texas from offices in Dallas and Austin. Her clinical focus is perimenopause, hormone imbalance, gut health, thyroid and autoimmune conditions, and chronic fatigue.
More about Anna · Schedule a consultation · LinkedIn · Instagram
Medical disclaimer. The information on this page is provided for general education and is not individualized medical advice. At Interlinked Wellness, Anna Evans, MSN, APRN, FNP-C, provides personalized care based on your health history, symptoms, concerns, and goals. An individual consultation allows Anna to evaluate your specific situation and recommend an appropriate approach to care. Reading this page alone does not establish a patient-provider relationship. If you are experiencing a medical emergency, call 911 or your local emergency services.
Join Anna on a virtual wellness journey and unlock your full potential.
